Route |
Drug |
Mechanism of Action |
Dose |
Comments |
Oral |
|
Gabapentin |
Structural analogues of γ-aminobutyric acid bind to α2δ subunit of voltage-dependent calcium channels and modify the action of a subset of N-methyl-D-aspartate-sensitive glutamate receptors, M-channel, neurexin-1α, and thrombospondin proteins |
400 mg |
Sedation, nausea, and vomiting especially in the elderly and renal impairment patients |
|
Pregabalin |
150 mg |
|
Celecoxib |
Selective COX-2 inhibitors |
200 mg |
Increased cardiovascular risk in ischemic patients |
Intravenous |
Nonopioid |
|
Paracetamol |
A centrally acting drug, which suppresses prostaglandin synthesis and cyclooxygenase (COX) |
1 g |
Well-tolerated drug |
|
NSAID |
Inhibit both the COX-1 and COX-2 enzymes |
|
-
Platelet dysfunction
-
Renal dysfunction
-
Peptic ulcer |
|
Ketamine |
N-methyl-D-aspartate receptor antagonist and binds to γ-aminobutyric acid, cholinergic, and voltage-gated sodium channel |
0.15-0.5 mg/kg |
Psychotomimetic side effects |
|
Magnesium sulphate |
Antagonist of calcium channels and N-methyl-D-aspartate receptors |
50 mg/kg |
Reduction of requirement of propofol (induction and maintenance), neuromuscular blocking agents, and fentanyl |
Opioid |
Opioid receptor agonist |
Mu, kappa, and delta receptor agonist |
|
|
Regional |
|
|
Intrathecal and epidural agents |
Opioid receptor agents (diamorphine) |
|
Surgical wound infiltration |
Bupivacaine, levobupivacaine, liposomal bupivacaine |
Amide local anesthetics, which inactivate voltage-dependent sodium channels |
|
|
Peripheral nerve block |
|